Calidi Biotherapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021
Market Capitalization	8	54	100	282
Market Cap Growth	-	-46.74%	-64.38%	-
Enterprise Value	13	59	135	301
PE Ratio	-1.83	-1.83	-3.95	-25.80
PS Ratio	-	-	2232.43	628.15
PB Ratio	-6.50	-6.50	-1.99	-8.92
P/FCF Ratio	-1.94	-1.94	-7.36	-35.34
P/OCF Ratio	-1.98	-1.98	-7.60	-36.28
EV/Sales Ratio	-	-	3005.90	670.14
EV/EBITDA Ratio	-2.19	-2.19	-5.41	-29.64
EV/EBIT Ratio	-2.09	-2.09	-5.36	-29.19
EV/FCF Ratio	-2.13	-2.13	-9.92	-37.71
Debt / Equity Ratio	-0.88	-0.88	-0.70	-0.66
Debt / EBITDA Ratio	-0.27	-0.27	-1.41	-2.07
Debt / FCF Ratio	-0.26	-0.26	-2.58	-2.63
Quick Ratio	0.19	0.19	0.01	0.08
Current Ratio	0.42	0.42	0.02	0.11
Interest Coverage	-26.32	-26.32	-159.86	-16.79
Return on Equity (ROE)	91.20%	91.20%	122.80%	-
Return on Assets (ROA)	-248.40%	-248.40%	-20.10%	-
Return on Capital (ROIC)	2902.10%	2902.10%	151.54%	98.70%
Earnings Yield	-371.34%	-54.60%	-25.31%	-3.88%
FCF Yield	-350.39%	-51.52%	-13.58%	-2.83%
Buyback Yield / Dilution	-98.55%	-98.55%	56.93%	-
Total Shareholder Return	-98.55%	-98.55%	56.93%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).